BrainStorm Cell Therapeutics (BCLI) Update 11112024
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for NDDs – BCLI’s first target is ALS (MND/Lou Gehrig’s). BLCI’s Expanded Access Program (EAP), a compassionate use study, delivered >96% probability that BCLI’s NurOwn® treatment was responsible for an improved survival rate in a test group of 10 ALS patients. BCLI recently regained Nasdaq price compliance, released two posters for NurOwn® and presented at Maxim’s healthcare summit. We infer that BCLI has a reasonable chance of reaching the final award decision stage for up to US$50m non-dilutive matched funding. A successful EAP provides real world evidence outside of a formal trial that may help accelerate both non-dilutive funding decisions and regulatory approval.
ACF Equity Research is an independent research house specialising in the highest specification independent equity research for corporate clients.
We deliver premium independent corporate sponsored equity research characterised by its accuracy, clarity and foresight based upon a fundamental valuation approach.
Our independent research is designed to educate our professional investor readers with an emphasis on clear and accurate explanations. Our mission is to improve company’s liquidity through credible equity research services, excellent international distribution and reliable access for investment managers.
We believe in the importance and value of clarity, the careful articulation of technical ideas, concepts and solutions.
Our team of analysts are independently minded individuals who believe in thoroughness, technical competence and clear punchy communications.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.